Blog

Gertjan Rasschaert: TCR dynamics after first dose BOTBAL are predictive for response

Gertjan Rasschaert/LinkedIn

Jun 1, 2025, 09:00

Gertjan Rasschaert: TCR dynamics after first dose BOTBAL are predictive for response

Gertjan Rasschaert, Medical Doctor and Consultant specializing in Gastrointestinal Oncology and Gastroenterology at UZ Leuven, shared a post on LinkedIn:

“Proud of our work we presented today at ASCO25. Glad to see the buzz we were generate. Happy to discuss lots of genuine questions with peers from around the globe.

Two key takeaway points:

1) TCR dynamics after first dose (!) BOTBAL are predictive for response.

2) Clinically meaning full responses not captured per RESIST can be captured by TCR sequencing.

This wouldn’t have been possible without the swift collaboration between:

KU Leuven UZ Leuven: Sabine Tejpar, Filip Van Herpe, Allyson Peddle, Sofie Gielis, Robin Govaerts.”

Rasschaert shared highlights from ASCO25, focusing on findings that suggest early TCR dynamics following BOTBAL treatment may serve as predictors of therapeutic response. He also emphasized the value of TCR sequencing in detecting clinically meaningful responses not captured by standard RECIST criteria.

More posts featuring Gertjan Rasschaert.

Allyson Peddle ASCO25 BOTBAL cancer fight against cancer Filip Van Herpe Gastroenterology Gastrointestinal Oncology Gertjan Rasschaert Global fight against cancer OncoDaily Oncology Robin Govaerts Sabine Tejpar Sofie Gielis TCR sequencing UZ Leuven

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment

15 Posts Not to Miss from the 2nd Day of ASCO 2025

15 Posts Not to Miss from the 1st Day of ASCO 2025

Wafik El-Deiry: Inside Yvonne Award Ceremony 2025